Limbal Stem Cell Deficiency
Conditions
Brief summary
The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial allograft from living-related donor is more effective than limbal conjunctival allograft from living-related donor for ocular surface reconstruction in patients with limbal stem cell deficiency (LSCD).
Interventions
PROCEDURECorneal epithelial allograft
A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
PROCEDURELimbal conjunctival allograft
A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
DEVICEFemtosecond laser
A commercial femtosecond laser to create a particular shaped graft for transplantation
DEVICEDiamond knife
A diamond knife to create a particular shaped limbal graft for transplantation
Sponsors
Chunxiao Wang
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. LSCD secondary to ocular burns, with the duration of disease of at least 24 months at the time of screening visit; 2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea; 3. Having a human leukocyte antigen (HLA)-matched living-related donor (≥4/6 HLA-A/B/DR matched); 4. Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study.
Exclusion criteria
Recipients: 1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement; 2. LSCD by ocular surface disorders other than ocular burn; 3. Eyelids malposition; 4. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm; 5. High myopia with a spherical equivalent of -15.0 D or less; 6. Corneal or ocular surface infection within 30 days prior to study entry; 7. Ocular surface malignancy; 8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%; 9. Renal failure with creatinine clearance\< 25ml/min; 10. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L; 11. Platelet levels \< 150,000 or \> 450,000 per microliter; 12. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female); 13. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 14. Pregnancy (positive test) or lactation; 15. Participation in another simultaneous medical investigation or clinical trial; 16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening; 17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases; 18. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye; 19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 20. Signs of current infection, including fever and treatment with antibiotics; 21. Active immunological diseases; 22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries. Donors: 1. Cornea diseases (epithelial defects, neovascularization, etc.); 2. Eyelids malposition; 3. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm; 4. High myopia with a spherical equivalent of -15.0 D or less; 5. Corneal or ocular surface infection within 30 days prior to study entry; 6. Ocular surface malignancy; 7. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%; 8. Renal failure with creatinine clearance\< 25ml/min; 9. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L; 10. Platelet levels \< 150,000 or \> 450,000 per microliter; 11. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female); 12. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 13. Pregnancy (positive test) or lactation; 14. Participation in another simultaneous medical investigation or clinical trial; 15. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening; 16. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases; 17. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye; 18. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 19. Signs of current infection, including fever and treatment with antibiotics; 20. Active immunological diseases; 21. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Restoration of corneal surface in the recipient | 1 year | Restoration of a completely epithelized, stable, and avascular corneal surface in the recipient |
| Restoration of corneal surface in the donor | 1 year | Restoration of a completely epithelized, stable, and avascular corneal surface in the donor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Corneal sensation of recipients and donors | 1 year | To measure corneal sensation using Cochet-Bonnet esthesiometer. |
| Corneal thickness of recipients and donors | 1 year | To measure corneal thickness using Anterior Segment Optical Coherence Tomograph (AS-OCT). |
| Density of stromal nerve and stromal keratocytes of recipients and donors | 1 year | To measure density of stromal nerve and stromal keratocytes using in vivo confocal microscopy |
| Uncorrected and best-corrected visual acuity of recipients and donors | 1 year | To assess changes of uncorrected and best-corrected visual acuity using ETDRS chart. |
| Corneal graft rejection of recipients | 1 year | To assess corneal graft rejection using slit-lamp microscopy. |
| Corneal haze of recipients and donors | 1 year | To assessing corneal haze using in vivo confocal microscopy |
| Reconstruction of limbal palisades of Vogt of recipients | 1 year | To assess reconstruction of limbal palisades of Vogt using in vivo confocal microscopy. |
| Corneal power, astigmatism and aberration of recipients and donors | 1 year | To measure changes of corneal power, astigmatism and aberration using autorefractor keratometer and wavefront aberrometer respectively. |
Countries
China
Outcome results
None listed